Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
| Revenue (TTM) | $450.89M |
| Gross Profit (TTM) | $338.28M |
| EBITDA | $-32.11M |
| Operating Margin | -10.30% |
| Return on Equity | -38.60% |
| Return on Assets | -4.25% |
| Revenue/Share (TTM) | $1.84 |
| Book Value | $0.60 |
| Price-to-Book | 6.02 |
| Price-to-Sales (TTM) | 1.96 |
| EV/Revenue | 1.933 |
| EV/EBITDA | 130.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.80% |
| Shares Outstanding | $258.19M |
| Float | $210.66M |
| % Insiders | 3.17% |
| % Institutions | 73.22% |
Volatility is currently expanding
Robbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth
New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/16/2026
LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
New York, New York--(Newsfile Corp. - September 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX).
LOS ANGELES, Sept. 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ardelyx, Inc., (“Ardelyx” or the "Company") (NASDAQ: ARDX) investors of a class action on behalf of investors that bought securities between January 13, 2025 and August 6, 2026, inclusive (the “Class Period”). Ardelyx investors have until November 16, 2026 to file a lead plaintiff motion.
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) on behalf of investors that purchased or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Ardelyx and have suffered losses, you may CLICK HERE to contact us.
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while payer prior authorization and step edit requirements were allegedly restricting IBSRELA and XPHOZAH prescriptions. NEW YORK, Sept.
New York, New York--(Newsfile Corp. - September 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
Ardelyx's chief executive, two successive chief financial officers, and its chief commercial officer are each named as individual defendants in a securities class action alleging they controlled public statements projecting $1.75 billion in combined peak sales for XPHOZAH and IBSRELA while payer access barriers were allegedly building. NEW YORK, Sept.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARDX and any ticker you trade — then tracks every position and per-strategy win rate.
